4-[[2-(4-fluorophenyl)pyrimidin-4-yl]amino]-N-[3-(2-methylpiperidin-1-yl)propyl]benzamide
C26H30FN5O — CID 53078208
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[[2-(4-fluorophenyl)pyrimidin-4-yl]amino]-N-[3-(2-methylpiperidin-1-yl)propyl]benzamide
4-[[2-(4-fluorophenyl)pyrimidin-4-yl]amino]-N-[3-(2-methylpiperidin-1-yl)propyl]benzamide (PubChem CID 53078208) has the molecular formula C26H30FN5O and a molecular weight of 447.56 g/mol. Its IUPAC name is 4-[[2-(4-fluorophenyl)pyrimidin-4-yl]amino]-N-[3-(2-methylpiperidin-1-yl)propyl]benzamide.
Molecular Properties
| Compound Name | 4-[[2-(4-fluorophenyl)pyrimidin-4-yl]amino]-N-[3-(2-methylpiperidin-1-yl)propyl]benzamide |
|---|---|
| PubChem CID | 53078208 |
| Molecular Formula | C26H30FN5O |
| Molecular Weight | 447.56 g/mol |
| Exact Mass | 447.24 |
| IUPAC Name | 4-[[2-(4-fluorophenyl)pyrimidin-4-yl]amino]-N-[3-(2-methylpiperidin-1-yl)propyl]benzamide |
| SMILES | CC1CCCCN1CCCNC(=O)c1ccc(Nc2ccnc(-c3ccc(F)cc3)n2)cc1 |
| InChI | InChI=1S/C26H30FN5O/c1-19-5-2-3-17-32(19)18-4-15-29-26(33)21-8-12-23(13-9-21)30-24-14-16-28-25(31-24)20-6-10-22(27)11-7-20/h6-14,16,19H,2-5,15,17-18H2,1H3,(H,29,33)(H,28,30,31) |
| InChIKey | REVXFUVDDXRASR-UHFFFAOYSA-N |
| XLogP | 5.02 |
| TPSA | 70.15 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 447.56 |
| LogP ≤ 5 | 5.02 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 53078208 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.